Mesothelioma Clinical Trial Studies Keytruda, Lenvatinib Combination
The objective response rate of the Keytruda/lenvatinib combination was an impressive 58%.
In 2020, the U.S. Food and Drug Administration approved the use of Keytruda for certain metastatic tumors, including certain cases of mesothelioma, but the search for an effective combination continues.
Lenvatinib has shown it can block tumor growth by targeting specific proteins Keytruda can’t reach. It has been effective with only select cancers and is known as precision medicine.
The drug, which is already FDA approved, has been used successfully with Keytruda for the treatment of endometrial cancer. Lenvatinib is prescr...
Source: Asbestos and Mesothelioma News - August 17, 2022 Category: Environmental Health Authors: Fran Mannino Tags: Clinical Trials/Research/Emerging Treatments Pleural Source Type: news
UK Approves Opdivo/Yervoy Immunotherapy for Pleural Mesothelioma
Patients with unresectable pleural mesothelioma cancer throughout the United Kingdom will now have the immunotherapy combination of Opdivo and Yervoy as an option after its recent approval by the National Health Service for first-line treatment.
The long-awaited approval comes almost two years after the U.S. Food and Drug Administration granted a similar approval of Opdivo and Yervoy. It brings new hope to a region particularly hard hit by this rare cancer caused primarily by exposure to asbestos.
Opdivo and Yervoy, known generically as nivolumab and ipilimumab, respectively, are manufactured by Bristol Myers Squibb....
Source: Asbestos and Mesothelioma News - July 27, 2022 Category: Environmental Health Authors: Fran Mannino Tags: Immunotherapy Mesothelioma Treatment Source Type: news
Toronto Cancer Center Hosts SMARTEST Mesothelioma Clinical Trial
Princess Margaret Cancer Centre in Toronto recently opened a first-of-its-kind clinical trial that hopes to build on earlier pioneering efforts to turn pleural mesothelioma into a more manageable, potentially survivable disease. Expectations are high.
This single-center phase II clinical trial is named SMARTEST, and follows in the wake of earlier mesothelioma trials SMART and SMARTER in Toronto. SMARTEST is an acronym for Surgery for Mesothelioma After Radiation Therapy using Exquisite Systemic Therapy.
“The hope is that we find an effective therapy with little toxicity. That’s the dream for every cancer doctor,...
Source: Asbestos and Mesothelioma News - June 28, 2022 Category: Environmental Health Authors: Fran Mannino Tags: Clinical Trials/Research/Emerging Treatments Source Type: news
Mesothelioma Clinical Trials Test Targeted Gene Therapy
For some patients, the future of mesothelioma cancer treatment may hinge on a pair of phase I clinical trials that opened earlier this year to study promising new drugs targeting specific genetic mutations.
Precision medicine may finally be taking hold with malignant mesothelioma, clearing the path for significant, long-overdue advancements.
The one-size-fits-all approach is fading.
“There is some realistic hope now for patients,” Dr. Anthony Tolcher, co-founder of NEXT Oncology in San Antonio, told The Mesothelioma Center at Asbestos.com. “I am very optimistic. New avenues for treatment are opening up.”
...
Source: Asbestos and Mesothelioma News - June 21, 2022 Category: Environmental Health Authors: Fran Mannino Tags: Clinical Trials/Research/Emerging Treatments Source Type: news
Novel Clinical Trial Helping Late-Stage Mesothelioma Patients
Late-stage patients with pleural mesothelioma have survived longer than anticipated — with good quality of life — in a phase I clinical trial studying the effectiveness of a novel combination treatment.
The treatment involves galinpepimut-S, the latest targeted cancer vaccine also known as GPS, in combination with Opdivo, a popular immunotherapy drug.
Memorial Sloan Kettering Cancer Center is hosting the study sponsored by SELLAS Life Sciences Group, a late-stage clinical biopharmaceutical company based in New York City.
“We’ve seen some very, very positive results,” Dr. Dragan Cicic, director of Clinica...
Source: Asbestos and Mesothelioma News - June 14, 2022 Category: Environmental Health Authors: Sophia Clifton Tags: Clinical Trials/Research/Emerging Treatments Source Type: news
FDA approves Opdivo in combination with chemotherapy and Opdivo in combination with Yervoy for first-line esophageal squamous cell carcinoma indications
(Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - May 31, 2022 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Immunotherapy Now First Line for Esophageal Cancer Immunotherapy Now First Line for Esophageal Cancer
Nivolumab (Opdivo) with chemotherapy or in combination with ipilimumab (Yervoy) has been approved by the FDA for first-line use in the treatment of unresectable advanced or metastatic esophageal cancer.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 30, 2022 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
U.S. Food and Drug Administration Approves Two Opdivo (nivolumab)-Based Regimens as First-Line Treatments for Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Opdivo in combination with chemotherapy and Opdivo plus Yervoy® (ipilimumab) approved based on a Phase 3 trial showing improved overall survival versus chemotherapy alone1,2
Opdivo-based treatments are now approved for five indications in... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 30, 2022 Category: Drugs & Pharmacology Source Type: news
New Mesothelioma Immunotherapy Clinical Trial Opens at MD Anderson
The acclaimed MD Anderson Cancer Center in Houston is opening a phase II clinical trial involving a new immunotherapy drug aimed specifically at advanced, rare cancers, including both pleural and peritoneal mesothelioma.
This single-institution clinical trial will be measuring the safety and effectiveness of vudalimab, also known as XmAb20717, which was designed by the California-based biopharmaceutical company Xencor.
Vudalimab’s uniqueness stems from its ability to block the activation of cell surface proteins PD-1 and CTLA-4. These proteins stop the immune system from working properly and promote T-cell acti...
Source: Asbestos and Mesothelioma News - May 11, 2022 Category: Environmental Health Authors: Fran Mannino Tags: Clinical Trials/Research/Emerging Treatments Source Type: news
Dual Immunotherapy Improves PFS in Melanoma Resistant to Anti-PD-1
(MedPage Today) -- NEW ORLEANS -- Nivolumab (Opdivo) plus ipilimumab (Yervoy) improved outcomes compared with ipilimumab alone for patients with advanced melanoma who have primary resistance to PD-1 inhibitors, a randomized study found.
While... (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - April 13, 2022 Category: Dermatology Source Type: news
Nivolumab Combo Treats Advanced Esophageal Squamous - Cell Carcinoma
Overall survival longer in patients receiving first - line treatment with nivolumab plus chemo or nivolumab plus ipilimumab versus chemo alone (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - February 3, 2022 Category: Cancer & Oncology Tags: Gastroenterology, Oncology, Pharmacy, Journal, Source Type: news
Nivolumab Combo Treats Advanced Esophageal Squamous-Cell Carcinoma
THURSDAY, Feb. 3, 2022 -- For patients with previously untreated, advanced esophageal squamous cell carcinoma, treatment with nivolumab plus chemotherapy or nivolumab plus ipilimumab results in significantly longer overall survival than chemotherapy... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 3, 2022 Category: Pharmaceuticals Source Type: news
NCI Opens New Immunotherapy Clinical Trial for Mesothelioma
This study offers a reasonable chance of benefit. It would be nice to see if these patients again respond to immunotherapy.”
The FDA approved Opdivo and Yervoy, an immunotherapy combination, for first-line treatment of pleural mesothelioma in 2020. It was the first new systemic approval in more than 16 years. However, it only increased the median overall survival time from 14.1 months to 18.1 months, when compared to standard chemotherapy.
Find Immunotherapy Clinical Trials
...
Source: Asbestos and Mesothelioma News - January 4, 2022 Category: Environmental Health Authors: Chris Elkins Source Type: news
Clinical Trials Lead to Promising Updates in Mesothelioma Immunotherapy
This study recruited patients with unresectable pleural mesothelioma who had not received prior chemotherapy.
The primary endpoint of median overall survival was significantly longer with the addition of bevacizumab to chemotherapy at 18.8 months versus 16.1 months with chemotherapy alone. However, adverse events such as hypertension and bleeding were more common in the bevacizumab group.
More recently, studies such as the phase II RAMSES trial in 2020 have shown promising results for combining anti-VEGF medication with chemotherapy as a second-line treatment. The addition of the VEGF inhibitor ramucirumab significan...
Source: Asbestos and Mesothelioma News - December 8, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news
Mesothelioma Clinical Trial to Involve Drug Studied for COVID-19
A novel phase II clinical trial for malignant mesothelioma is expected to open soon and involve a versatile, biological drug already showing promise in treating severe cases of COVID-19.
Oncotelic Therapeutics Inc., an innovative, immunotherapy/oncology company in Agoura Hills, California, hopes to open the mesothelioma clinical trial by March at a dozen prominent U.S. treatment centers, including the Cleveland Clinic Cancer Center, University of Pennsylvania Medicine in Philadelphia and Fred Hutchinson Cancer Research Center in Seattle.
“We’re excited about the potential. There is a huge unmet medical need with ...
Source: Asbestos and Mesothelioma News - December 7, 2021 Category: Environmental Health Authors: Chris Elkins Source Type: news
